BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22258666)

  • 1. Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer.
    Rubio IT; Cebrecos I; Peg V; Esgueva A; Mendoza C; Cortadellas T; Cordoba O; Espinosa-Bravo M; Xercavins J
    J Surg Oncol; 2012 Jul; 106(1):89-93. PubMed ID: 22258666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy.
    Boneti C; Korourian S; Bland K; Cox K; Adkins LL; Henry-Tillman RS; Klimberg VS
    J Am Coll Surg; 2008 May; 206(5):1038-42; discussion 1042-4. PubMed ID: 18471751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer.
    Ponzone R; Cont NT; Maggiorotto F; Cassina E; Mininanni P; Biglia N; Sismondi P
    J Clin Oncol; 2009 Nov; 27(33):5547-51. PubMed ID: 19826123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kinoshita T; Takasugi M; Iwamoto E; Akashi-Tanaka S; Fukutomi T; Terui S
    Am J Surg; 2006 Feb; 191(2):225-9. PubMed ID: 16442950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary reverse mapping: a prospective study in women with clinically node negative and node positive breast cancer.
    Connor C; McGinness M; Mammen J; Ranallo L; Lafaver S; Klemp J; Fan F; Mahnken J
    Ann Surg Oncol; 2013 Oct; 20(10):3303-7. PubMed ID: 23975287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARM: axillary reverse mapping - the need for selection of patients.
    Gobardhan PD; Wijsman JH; van Dalen T; Klompenhouwer EG; van der Schelling GP; Los J; Voogd AC; Luiten EJ
    Eur J Surg Oncol; 2012 Aug; 38(8):657-61. PubMed ID: 22607749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients?
    Tausch C; Baege A; Dietrich D; Vergin I; Heuer H; Heusler RH; Rageth C
    Eur J Surg Oncol; 2013 Aug; 39(8):880-6. PubMed ID: 23735162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary reverse mapping (ARM) in clinically node positive breast cancer patients.
    Beek MA; Gobardhan PD; Klompenhouwer EG; Rutten HJ; Voogd AC; Luiten EJ
    Eur J Surg Oncol; 2015 Jan; 41(1):59-63. PubMed ID: 25468747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary reverse mapping using a fluorescence imaging system in breast cancer.
    Noguchi M; Noguchi M; Nakano Y; Ohno Y; Kosaka T
    J Surg Oncol; 2012 Mar; 105(3):229-34. PubMed ID: 21913193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer.
    Noguchi M; Yokoi M; Nakano Y
    J Surg Oncol; 2010 Mar; 101(3):217-21. PubMed ID: 20063370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of non-sentinel lymph node metastasis in breast cancer patients.
    Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE;
    Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
    Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
    Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer.
    Hirche C; Mohr Z; Kneif S; Murawa D; Hünerbein M
    J Surg Oncol; 2012 Feb; 105(2):162-6. PubMed ID: 21882198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients?
    Khandelwal R; Poovamma CU; Shilpy C; Prema M; Anthony P
    Breast Dis; 2014 Jan; 34(4):151-5. PubMed ID: 24934169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of direct oil contrast lymphography of upper limb lymphatics traversing the axilla -- a lesson from the past -- contribution to the concept of axillary reverse mapping.
    Pavlista D; Eliska O
    Eur J Surg Oncol; 2012 May; 38(5):390-4. PubMed ID: 22336143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.
    Helyer LK; Varnic M; Le LW; Leong W; McCready D
    Breast J; 2010; 16(1):48-54. PubMed ID: 19889169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.